Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
Rhea-AI Summary
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has scheduled its first quarter 2025 financial results conference call and webcast for May 1, 2025, at 8:00 a.m. ET. The event will cover Q1 2025 financial performance and business updates.
The webcast will be available through the Investors section of Agios' website under Events & Presentations, with a replay accessible approximately two hours after the event.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When will Agios Pharmaceuticals (AGIO) release Q1 2025 earnings?
How can investors access Agios Pharmaceuticals' Q1 2025 earnings call?
Will there be a replay available for Agios' Q1 2025 earnings webcast?
What will Agios Pharmaceuticals discuss in their Q1 2025 earnings call?
